Systems medicine approaches to improving understanding, treatment, and clinical management of neuroendocrine prostate cancer

Kamlesh K. Yadav, Khader Shameer, Benjamin Readhead, Shalini S. Yadav, Li Li, Andrew Kasarskis, Ashutosh K. Tewari, Joel T. Dudley

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: Prostate cancer is the most commonly diagnosed cancer in men. More than 200,000 new cases are added each year in the US, translating to a lifetime risk of 1 in 7 men. Neuroendocrine prostate cancer (NEPC) is an aggressive and treatmentresistant form of prostate cancer. A subset of patients treated with aggressive androgen deprivation therapy (ADT) present with NEPC. Patients with NEPC have a reduced 5-year overall survival rate of 12.6%. Knowledge integration from genetic, epigenetic, biochemical and therapeutic studies suggests NEPC as an indicative mechanism of resistance development to various forms of therapy. Methods: In this perspective, we discuss various experimental, computational and risk prediction methodologies that can be utilized to identify novel therapies against NEPC. We reviewed literature from PubMed and computationally analyzed publicly available genomics data to present different possibilities for developing systems medicine based therapeutic and curative models to understand and target prostate cancer and NEPC. Results: We discuss strategies including gene-set analyses, network analyses, genomics and phenomics aided drug development, microRNA and peptide-based therapeutics, pathway modeling, drug repositioning and cancer immunotherapies. We also discuss the application of cancer risk estimations and mining of electronic medical records to develop personalized risk predictions models for NEPC. Preemptive stratification of patients who are at risk of evolving NEPC phenotypes using predictive models could also help to design and deliver better therapies. Conclusion: Collectively, understanding the mechanism of NEPC evolution from prostate cancer using systems biology approaches would help in devising better treatment strategies and is critical and unmet clinical need.

Original languageEnglish (US)
Pages (from-to)5234-5248
Number of pages15
JournalCurrent Pharmaceutical Design
Volume22
Issue number34
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Systems Analysis
Prostatic Neoplasms
Therapeutics
Genomics
Drug Repositioning
Neoplasms
Systems Biology
Electronic Health Records
MicroRNAs
PubMed
Epigenomics
Immunotherapy
Androgens
Molecular Biology
Survival Rate

Keywords

  • Neuroendocrine prostate cancer
  • Precision medicine
  • Prostate cacner
  • Systems biology

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Systems medicine approaches to improving understanding, treatment, and clinical management of neuroendocrine prostate cancer. / Yadav, Kamlesh K.; Shameer, Khader; Readhead, Benjamin; Yadav, Shalini S.; Li, Li; Kasarskis, Andrew; Tewari, Ashutosh K.; Dudley, Joel T.

In: Current Pharmaceutical Design, Vol. 22, No. 34, 01.09.2016, p. 5234-5248.

Research output: Contribution to journalReview article

Yadav, Kamlesh K. ; Shameer, Khader ; Readhead, Benjamin ; Yadav, Shalini S. ; Li, Li ; Kasarskis, Andrew ; Tewari, Ashutosh K. ; Dudley, Joel T. / Systems medicine approaches to improving understanding, treatment, and clinical management of neuroendocrine prostate cancer. In: Current Pharmaceutical Design. 2016 ; Vol. 22, No. 34. pp. 5234-5248.
@article{7980bf0117714feaa19b3b6622f3114c,
title = "Systems medicine approaches to improving understanding, treatment, and clinical management of neuroendocrine prostate cancer",
abstract = "Background: Prostate cancer is the most commonly diagnosed cancer in men. More than 200,000 new cases are added each year in the US, translating to a lifetime risk of 1 in 7 men. Neuroendocrine prostate cancer (NEPC) is an aggressive and treatmentresistant form of prostate cancer. A subset of patients treated with aggressive androgen deprivation therapy (ADT) present with NEPC. Patients with NEPC have a reduced 5-year overall survival rate of 12.6{\%}. Knowledge integration from genetic, epigenetic, biochemical and therapeutic studies suggests NEPC as an indicative mechanism of resistance development to various forms of therapy. Methods: In this perspective, we discuss various experimental, computational and risk prediction methodologies that can be utilized to identify novel therapies against NEPC. We reviewed literature from PubMed and computationally analyzed publicly available genomics data to present different possibilities for developing systems medicine based therapeutic and curative models to understand and target prostate cancer and NEPC. Results: We discuss strategies including gene-set analyses, network analyses, genomics and phenomics aided drug development, microRNA and peptide-based therapeutics, pathway modeling, drug repositioning and cancer immunotherapies. We also discuss the application of cancer risk estimations and mining of electronic medical records to develop personalized risk predictions models for NEPC. Preemptive stratification of patients who are at risk of evolving NEPC phenotypes using predictive models could also help to design and deliver better therapies. Conclusion: Collectively, understanding the mechanism of NEPC evolution from prostate cancer using systems biology approaches would help in devising better treatment strategies and is critical and unmet clinical need.",
keywords = "Neuroendocrine prostate cancer, Precision medicine, Prostate cacner, Systems biology",
author = "Yadav, {Kamlesh K.} and Khader Shameer and Benjamin Readhead and Yadav, {Shalini S.} and Li Li and Andrew Kasarskis and Tewari, {Ashutosh K.} and Dudley, {Joel T.}",
year = "2016",
month = "9",
day = "1",
doi = "10.2174/1381612822666160513145924",
language = "English (US)",
volume = "22",
pages = "5234--5248",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "34",

}

TY - JOUR

T1 - Systems medicine approaches to improving understanding, treatment, and clinical management of neuroendocrine prostate cancer

AU - Yadav, Kamlesh K.

AU - Shameer, Khader

AU - Readhead, Benjamin

AU - Yadav, Shalini S.

AU - Li, Li

AU - Kasarskis, Andrew

AU - Tewari, Ashutosh K.

AU - Dudley, Joel T.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: Prostate cancer is the most commonly diagnosed cancer in men. More than 200,000 new cases are added each year in the US, translating to a lifetime risk of 1 in 7 men. Neuroendocrine prostate cancer (NEPC) is an aggressive and treatmentresistant form of prostate cancer. A subset of patients treated with aggressive androgen deprivation therapy (ADT) present with NEPC. Patients with NEPC have a reduced 5-year overall survival rate of 12.6%. Knowledge integration from genetic, epigenetic, biochemical and therapeutic studies suggests NEPC as an indicative mechanism of resistance development to various forms of therapy. Methods: In this perspective, we discuss various experimental, computational and risk prediction methodologies that can be utilized to identify novel therapies against NEPC. We reviewed literature from PubMed and computationally analyzed publicly available genomics data to present different possibilities for developing systems medicine based therapeutic and curative models to understand and target prostate cancer and NEPC. Results: We discuss strategies including gene-set analyses, network analyses, genomics and phenomics aided drug development, microRNA and peptide-based therapeutics, pathway modeling, drug repositioning and cancer immunotherapies. We also discuss the application of cancer risk estimations and mining of electronic medical records to develop personalized risk predictions models for NEPC. Preemptive stratification of patients who are at risk of evolving NEPC phenotypes using predictive models could also help to design and deliver better therapies. Conclusion: Collectively, understanding the mechanism of NEPC evolution from prostate cancer using systems biology approaches would help in devising better treatment strategies and is critical and unmet clinical need.

AB - Background: Prostate cancer is the most commonly diagnosed cancer in men. More than 200,000 new cases are added each year in the US, translating to a lifetime risk of 1 in 7 men. Neuroendocrine prostate cancer (NEPC) is an aggressive and treatmentresistant form of prostate cancer. A subset of patients treated with aggressive androgen deprivation therapy (ADT) present with NEPC. Patients with NEPC have a reduced 5-year overall survival rate of 12.6%. Knowledge integration from genetic, epigenetic, biochemical and therapeutic studies suggests NEPC as an indicative mechanism of resistance development to various forms of therapy. Methods: In this perspective, we discuss various experimental, computational and risk prediction methodologies that can be utilized to identify novel therapies against NEPC. We reviewed literature from PubMed and computationally analyzed publicly available genomics data to present different possibilities for developing systems medicine based therapeutic and curative models to understand and target prostate cancer and NEPC. Results: We discuss strategies including gene-set analyses, network analyses, genomics and phenomics aided drug development, microRNA and peptide-based therapeutics, pathway modeling, drug repositioning and cancer immunotherapies. We also discuss the application of cancer risk estimations and mining of electronic medical records to develop personalized risk predictions models for NEPC. Preemptive stratification of patients who are at risk of evolving NEPC phenotypes using predictive models could also help to design and deliver better therapies. Conclusion: Collectively, understanding the mechanism of NEPC evolution from prostate cancer using systems biology approaches would help in devising better treatment strategies and is critical and unmet clinical need.

KW - Neuroendocrine prostate cancer

KW - Precision medicine

KW - Prostate cacner

KW - Systems biology

UR - http://www.scopus.com/inward/record.url?scp=84995899144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995899144&partnerID=8YFLogxK

U2 - 10.2174/1381612822666160513145924

DO - 10.2174/1381612822666160513145924

M3 - Review article

C2 - 27174811

AN - SCOPUS:84995899144

VL - 22

SP - 5234

EP - 5248

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 34

ER -